Cargando…

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by the upregulation of the Janus kinase (JAK)—signal transducer and activator of transcription (STAT) pathway with associated extramedullary hematopoiesis and a high burden of disease-related symptoms. While JAK inhibitor therapy is cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuykendall, Andrew T., Horvat, Nathan P., Pandey, Garima, Komrokji, Rami, Reuther, Gary W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464183/ https://www.ncbi.nlm.nih.gov/pubmed/32823910 http://dx.doi.org/10.3390/cancers12082278

Ejemplares similares

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
por: Pandey, Garima, et al.
Publicado: (2022)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Social Work for Jill
por: Toynbee, S. A.
Publicado: (1955)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Essays in Memory of Professor Jill Poole
por: Merkin, Rob, et al.
Publicado: (2018)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
por: Sousos, Nikolaos, et al.
Publicado: (2020)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
por: Pullarkat, V., et al.
Publicado: (2022)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Publicado: (2021)

JAK inhibitors for refractory lymphoma
por: Kimura, Hiroshi
Publicado: (2018)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6orvq3clrro8p1pe4tut1rflp1